Eton Pharmaceuticals, Inc. (ETON)
Valuation Overview•Is Eton Pharmaceuticals, Inc. Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Fragile underlying quality score of 45/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
ETON struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company is driving exceptional top-line expansion (55.5% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (2.3%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $24.3M | +104.9% | +55.5% | +359.6% | — | |
| EBITDA | $2.4M | — | — | — | — | |
| Net Income | $1.6M | -20.4% | +20.1% | — | — | |
| EPS (Diluted) | $0.05 | -13.3% | — | — | — | |
| Free Cash Flow | $7.3M | +980.7% | +71.1% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 54.8% | 60.0% | 67.1% | -35.0% |
| Operating Margin | 2.3% | -3.4% | -11.2% | -10215.9% |
| Net Margin | -1.7% | -6.2% | -14.0% | -10528.3% |
| FCF Margin | 17.8% | 11.4% | 1.5% | -8498.6% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.10 | $0.05 | -50.0% | ||
| Q1'26 | $0.12 | $0.05 | -58.3% | ||
| Q4'25 | $0.16 | $-0.07 | -143.8% | ||
| Q3'25 | $-0.01 | $-0.10 | -900.0% | ||
| Q2'25 | $0.09 | $0.07 | -22.2% | ||
| Q1'25 | $-0.02 | $-0.02 | +0.0% | ||
| Q4'24 | $0.00 | $0.02 | +400.0% | ||
| Q3'24 | $-0.07 | $-0.12 | -71.4% |
Total return is +137.1% (1Y), outperforming the benchmark by +112.1%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +99.8% | +90.4% | — |
| 1Y | +137.1% | +112.1% | — |
| 3YCAGR | +101.7% | +82.7% | — |
| 5YCAGR | +40.3% | +26.7% | — |
| 10YCAGR | +17.9% | +4.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Eton Pharmaceuticals, Inc. (ETON) valuation, health, and returns.
Based on peer relative multiples, Eton Pharmaceuticals, Inc. appears Expensive versus peers compared to industry peers.
Eton Pharmaceuticals, Inc. has multiple valuation anchors: Peer Relative Fair Value: $13.69 | Wall Street Analyst Target: $57.00 (implying +75.5% upside). A convergence of these signals offers higher conviction.
Eton Pharmaceuticals, Inc. displays fair financial health with a composite quality score of 45/100, supported by a Altman Z-Score of 7.3 (safe zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 0.2%.
Eton Pharmaceuticals, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Eton Pharmaceuticals, Inc.'s current growth trajectory is Accelerating. The company achieved +104.9% 1Y revenue growth and -13.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +55.5%.
Wall Street consensus is Buy based on 6 analysts, beating EPS expectations in 33% of recent quarters with a -6-quarter streak. The consensus price target represents a +75.5% change from current levels.
Investment risks for Eton Pharmaceuticals, Inc. include: -36.2% 1-year max drawdown. Volatility risk is characterized by a beta of 0.48x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.